Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation

被引：5

作者：

Zettl, Uwe Klaus ^{[1
,10
]}

Rommer, Paulus Stefan ^{[1
,2
]}

Aktas, Orhan ^{[3
]}

Wagner, Torsten ^{[4
]}

Richter, Joachim ^{[4
]}

Oschmann, Patrick ^{[5
]}

Cepek, Lukas ^{[6
]}

Elias-Hamp, Birte ^{[7
]}

Gehring, Klaus ^{[8
]}

Chan, Andrew ^{[9
]}

Hecker, Michael ^{[1
]}

机构：

[1] Rostock Univ, Med Ctr, Dept Neurol, Rostock, Germany

[2] Med Univ Vienna, Dept Neurol, Vienna, Austria

[3] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany

[4] Merck Healthcare Germany GmbH, Weiterstadt, Germany

[5] Bayreuth Hosp, Dept Neurol, Bayreuth, Germany

[6] Neurol Grp Practice, Ulm, Germany

[7] Neurol Private Practice, Hamburg, Germany

[8] Neuroctr Itzehoe, Itzehoe, Germany

[9] Univ Hosp Bern, Dept Neurol, Inselspital Bern, Bern, Switzerland

[10] Rostock Univ, Med Ctr, Dept Neurol, Div Neuroimmunol, Gehlsheimer Str 20, D-18147 Rostock, Germany

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2023年 / 19卷 / 11期

关键词：

Interferon beta-1a; multiple sclerosis; disease-modifying therapy; 25; years; generation; long-term efficacy; long-term safety; mechanisms of action; DISEASE-MODIFYING THERAPIES; MEMORY B-CELLS; RESOURCE UTILIZATION; GENE-EXPRESSION; DOUBLE-BLIND; IFN-BETA; ADHERENCE; MULTICENTER; TERM; ALEMTUZUMAB;

D O I：

10.1080/1744666X.2023.2248391

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IntroductionInterferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.Areas coveredBased on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses.Expert opinionIFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.

引用

页码：1343 / 1359

页数：17

共 192 条

[31]

Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670

[32] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[33] Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].

Comi, G ;

Filippi, M ;

Barkhof, F ;

Durelli, L ;

Edan, G ;

Fernández, O ;

Hartung, HP ;

Seeldrayers, P ;

Sorensen, PS ;

Rovaris, M ;

Martinelli, V ;

Hommes, OR .

LANCET, 2001, 357 (9268) :1576-1582

[34] Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study [J].

Comi, Giancarlo ;

De Stefano, Nicola ;

Freedman, Mark S. ;

Barkhof, Frederik ;

Uitdehaag, Bernard M. J. ;

de Vos, Marlieke ;

Marhardt, Kurt ;

Chen, Liang ;

Issard, Delphine ;

Kappos, Ludwig .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (04) :285-294

[35] Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial [J].

Comi, Giancarlo ;

De Stefano, Nicola ;

Freedman, Mark S. ;

Barkhof, Frederik ;

Polman, Chris H. ;

Uitdehaag, Bernard M. J. ;

Casset-Semanaz, Florence ;

Hennessy, Brian ;

Moraga, Margaretha Stam ;

Rocak, Sanda ;

Stubinski, Bettina ;

Kappos, Ludwig .

LANCET NEUROLOGY, 2012, 11 (01) :33-41

[36] Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic [J].

de Seze, Jerome ;

Maillart, Elisabeth ;

Gueguen, Antoine ;

Laplaud, David A. A. ;

Michel, Laure ;

Thouvenot, Eric ;

Zephir, Helene ;

Zimmer, Luc ;

Biotti, Damien ;

Liblau, Roland .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[37] Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study [J].

De Stefano, Nicola ;

Sormani, Maria Pia ;

Stubinski, Bettina ;

Blevins, Gregg ;

Drulovic, Jelena S. ;

Issard, Delphine ;

Shotekov, Penko ;

Gasperini, Claudio .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) :97-101

[38] Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis [J].

De Stefano, Nicola ;

Curtin, Francois ;

Stubinski, Bettina ;

Blevins, Gregg ;

Drulovic, Jelena ;

Issard, Delphine ;

Shotekov, Penko ;

Gasperini, Claudio .

MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (07) :888-892

[39] The cGAS-STING pathway as a therapeutic target in inflammatory diseases [J].

Decout, Alexiane ;

Katz, Jason D. ;

Venkatraman, Shankar ;

Ablasser, Andrea .

NATURE REVIEWS IMMUNOLOGY, 2021, 21 (09) :548-569

[40] Seasonal adherence to, and effectiveness of, subcutaneous interferon-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study [J].

Deftereos, Spyros N. ;

Koutlas, Evangelos ;

Koutsouraki, Efrosini ;

Kyritsis, Athanassios ;

Papathanassopoulos, Panagiotis ;

Fakas, Nikolaos ;

Tsimourtou, Vaia ;

Vlaikidis, Nikolaos ;

Tavernarakis, Antonios ;

Voumvourakis, Konstantinos ;

Arvanitis, Michalis ;

Sakellariou, Dimitrios ;

DeLorenzo, Filippo .

BMC NEUROLOGY, 2018, 18

← 1 2 3 4 5 6 7 8 9 10 →